three years of telehealth threads, summarised so you do not have to read them
Posting this as a discussion rather than a claim: three years of telehealth threads, summarised so you do not have to read them.
Why "compounded" is not "generic", written out because the confusion is constant.
A generic is an approved product demonstrated to be bioequivalent to a reference. A compounded preparation is made for a patient or, in the case of an outsourcing facility, under a different regulatory route entirely. It carries no equivalence claim and it is not required to demonstrate one.
That is not a quality judgement. Plenty of compounded preparations are made carefully in facilities with real testing programmes. It is a statement about what has and has not been established, and the difference matters when people assume the two are interchangeable.
The five questions worth asking before you commit to any compounded arrangement.
Which facility, by name. Whether it is a 503A pharmacy or a 503B outsourcing facility. What concentration is on the label. What the beyond-use date is based on. Whether there is potency testing on the finished preparation rather than only on the starting material.
All five are answerable in one email and the pattern of what comes back is more informative than any of the individual answers. An organisation with a quality system finds these questions ordinary.
Asked for potency testing on the finished preparation. They had it. I had assumed they would not.
If somebody has the same thing measured a different way, post it next to mine and we will see whether they agree.
best — the order this archive was captured in
Nothing in this thread is medical advice, and the choice between arrangements is one for you and a prescriber who knows your history.
Careful. Naming a clinic without describing what actually happened turns this into a different kind of thread.
Potency and sterility testing on the finished preparation are separate from any certificate covering the starting material. Ask which you are being shown.
Agreed on potency testing of the finished preparation. That is a different question from the purity of the starting material.
Right, and the concentration genuinely can differ from the branded product, which breaks people’s arithmetic.
the price difference is mostly the intake, not the vial
the shortage list is the whole legal hinge and people skip it
Compounded preparations are not approved products and carry no bioequivalence claim. That is a statement about regulatory category, not about quality.
a telehealth intake that asks nothing has told you what it is
Compounded preparations are not approved products and carry no bioequivalence claim.
Agreed — and the follow-up question is what the beyond-use date is based on.
A 503A pharmacy compounds for an identified patient against a prescription. A 503B outsourcing facility registers with the regulator, may produce without patient-specific prescriptions, and is subject to current good manufacturing practice requirements. The two are governed differently and the difference is not cosmetic.
What is the beyond-use date and what is it based on?
That is not what patient-specific means. It refers to the prescription, not to a customisation of the formula.
The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which changes.
That is not what patient-specific means.
Adding one thing — ask for the facility name. Most will give it, and the ones that will not have answered you.
- 1Compounded preparations are not approved products and carry no…8 comments in this branch · started by u/quiet_moderator
- 2Nothing in this thread is medical advice, and the choice between…6 comments in this branch · started by u/vikram_mbeki